Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
Sign Up to like & getrecommendations! Published in 2019 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2019.1649378
Abstract: Abstract Objectives: To compare the efficacy of emicizumab prophylaxis with that of factor VIII (FVIII) prophylaxis in patients with hemophilia A without inhibitors using two approaches: network meta-analyses (NMA) and additional sub-group analyses from the… read more here.
Keywords: hemophilia without; prophylaxis; emicizumab prophylaxis; sub ... See more keywords
Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14667
Abstract: Emicizumab treatment may allow patients with hemophilia A without (PwHA) and with inhibitors (PwHA‐I) to undergo some minor surgeries, such as tooth extraction, without peri‐operative factor infusions. However, criteria for determining the necessity of factor… read more here.
Keywords: hemophilia without; peri operative; tooth extraction; operative hemostatic ... See more keywords
Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124421
Abstract: Introduction: The standard of care for patients with hemophilia A without inhibitors is factor VIII (FVIII) replacement therapy. The availability of non-factor therapy such as emicizumab (Hemlibra®; Genentech, Inc., South San Francisco, CA, USA) is… read more here.
Keywords: treatment; hemophilia without; prophylaxis; model ... See more keywords